The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Market Size Expansion Is Predicted For The Diagnostic Biomarkers Market Between 2026 And 2030?

The diagnostic biomarkers market size has seen rapid expansion in recent years. This market is expected to increase from $75.46 billion in 2025 to $87.47 billion in 2026, registering a compound annual growth rate (CAGR) of 15.9%. Historically, this growth can be linked to factors such as the rise in molecular diagnostics, the broadening scope of cancer research, the inherent limitations of traditional diagnostics, the increasing prevalence of chronic diseases, and advancements in biomarker validation studies.

The diagnostic biomarkers market is projected to experience significant expansion over the coming years, with its size anticipated to reach $155.92 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 15.5%. This growth during the forecast period is primarily fueled by advancements in omics technologies, the rise of personalized medicine, AI-based biomarker discovery, regulatory approvals for novel biomarkers, and the escalating demand for predictive diagnostics. Noteworthy trends expected in this timeframe include the increasing adoption of precision diagnostic biomarkers, a greater emphasis on genomic and proteomic biomarkers, the broadened use of biomarkers in oncology diagnostics, the integration of biomarker data with clinical analytics, and a growing necessity for early disease detection.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21171&type=smp

What Drivers Are Influencing The Diagnostic Biomarkers Market?

The expansion of the diagnostic biomarkers market going forward is driven by the increasing prevalence of cancer. The rising occurrence of cancer is attributed to factors like aging populations, changes in lifestyle, environmental exposures, and enhanced diagnostic abilities. Diagnostic biomarkers hold a crucial role in cancer by facilitating early detection, precise diagnosis, and customized treatment strategies, thereby improving patient outcomes. For instance, in January 2024, the American Cancer Society, a US-based nonprofit cancer advocacy organization, reported that the number of cancer cases climbed to 2,001,140, an increase from 1,958,310 in 2023, reflecting a growth of 2.19%. This escalating prevalence of cancer is a key factor fueling the growth of the diagnostic biomarkers market.

Which Market Segments Are Examined In The Diagnostic Biomarkers Market Study?

The diagnostic biomarkers market covered in this report is segmented –

1) By Product: Safety Biomarkers, Efficacy Biomarkers, Validation Biomarkers

2) By Application: Oncology, Metabolic Disease, Neurological Disease

3) By End User: Hospitals, Cancer Research Institutes, Diagnostic Labs

Subsegments:

1) By Safety Biomarkers: Toxicity Biomarkers, Organ-Specific Safety Biomarkers, Drug-Induced Injury Biomarkers

2) By Efficacy Biomarkers: Predictive Biomarkers, Prognostic Biomarkers, Pharmacodynamic Biomarkers

3) By Validation Biomarkers: Genomic Biomarkers, Proteomic Biomarkers, Metabolomic Biomarkers

Which Trends Are Shaping The Future Of The Diagnostic Biomarkers Market?

Leading companies in the diagnostic biomarkers market are concentrating on developing non-invasive testing approaches, such as blood-based biomarker tests, to improve patient comfort and accessibility while supporting personalized treatment strategies. A blood-based biomarker test functions as a diagnostic instrument that scrutinizes specific biological markers in the blood to identify or monitor conditions, like Alzheimer’s, in a minimally intrusive way. For instance, in July 2023, Quanterix Corporation, a US-based life sciences company, introduced LucentAD, a blood-based biomarker test created to assist healthcare providers in diagnosing Alzheimer’s disease (AD) in patients exhibiting early cognitive symptoms. The test measures plasma levels of phosphorylated tau protein at the 181 residue (p-Tau 181), a biomarker associated with amyloid pathology in the brain, a key indicator of AD. By offering a diagnostic tool that is less invasive and more accessible compared to conventional methods such as cerebrospinal fluid analysis or amyloid positron emission tomography, LucentAD aims to streamline the evaluation process for individuals suspected of having Alzheimer’s.

Who Are The Primary Competitors In The Diagnostic Biomarkers Market?

Major companies operating in the diagnostic biomarkers market are Johnson & Johnson Services Inc., F. Hoffmann-La Roche AG, Thermo Fisher Scientific Inc., Abbott Laboratories, PerkinElmer Inc., Siemens Healthineers AG, Merck KGaA, Agilent Technologies Inc., Charles River Laboratories International Inc., Bio-Rad Laboratories Inc., Bruker Corporation, Qiagen N.V., Myriad Genetics Inc., Meso Scale Diagnostics LLC, EKF Diagnostics Holdings Plc, Sino Biological Inc., Enzo Biochem Inc., Biomarker Technologies Inc., Cisbio Bioassays, Signosis Inc., Epigenomics AG, LifeSign LLC, Banyan Biomarkers Inc., Biosims Technologies SAS

Read the full diagnostic biomarkers market report here:

https://www.thebusinessresearchcompany.com/report/diagnostic-biomarkers-global-market-report

Which Regions Are Expected To Experience Rapid Expansion In The Diagnostic Biomarkers Market?

North America was the largest region in the diagnostic biomarkers market in 2025. The regions covered in the diagnostic biomarkers market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Diagnostic Biomarkers Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=21171&type=smp

Browse Through More Reports Similar to the Global Diagnostic Biomarkers Market 2026, By The Business Research Company

Biomarkers Global Market Report

https://www.thebusinessresearchcompany.com/report/biomarkers-global-market-report

Cancer Biomarker Global Market Report

https://www.thebusinessresearchcompany.com/report/cancer-biomarker-global-market-report

Oncology Biomarkers Global Market Report

https://www.thebusinessresearchcompany.com/report/oncology-biomarkers-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model